tbResList Print — mCHEMO MCT, metronomic chemo

Filters: qv=327, qv2=%, rfv=%

Product

mCHEMO MCT, metronomic chemo
Description: <b>Metronomic chemotherapy</b> refers to the therapeutic strategy of administering chemotherapeutic drugs at relatively low, minimally toxic doses on a frequent or continuous schedule without extended rest periods. This dosing regimen contrasts with traditional maximum tolerated dose (MTD) chemotherapy, which involves high doses given intermittently with breaks to allow patient recovery.<br>
<br>
-The drugs are given in lower doses and more frequently (often daily or multiple times a week) <br>
-Aims to consistently impair tumor growth mechanisms and potentially minimize the chance for cancer cells to recover<br>
-Aims to consistently impair tumor growth mechanisms and potentially minimize the chance for cancer cells to recover<br>
-With a lower dose intensity, patients often experience fewer and less severe side effects<br>


<p><b>Metronomic chemotherapy</b> — a chemotherapy dosing strategy in which conventional cytotoxic agents are administered at relatively low doses on a frequent, regular, or near-continuous schedule with minimal prolonged drug-free intervals. It is a treatment-scheduling modality rather than a single drug and is commonly abbreviated MCT, mCT, MC, or low-dose metronomic chemotherapy (LDM chemotherapy). Frequently studied agents include cyclophosphamide, capecitabine, methotrexate, vinorelbine, etoposide, and other conventional chemotherapeutics. Unlike maximum-tolerated-dose chemotherapy, its biological activity is not restricted to direct tumor-cell cytotoxicity; sustained effects on tumor endothelium, angiogenesis, immune suppression, stromal responses, and treatment-resistant cell populations are major components of the therapeutic rationale.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Sustained antiangiogenic activity through repeated injury or suppression of proliferating tumor endothelial cells, reduced vascular recovery between doses, and suppression of proangiogenic signaling including VEGF-related pathways.</li>
<li>Induction of antiangiogenic mediators, particularly thrombospondin-1, with consequent inhibition of endothelial proliferation and tumor neovascularization.</li>
<li>Immune modulation, especially depletion or functional suppression of regulatory T cells with some regimens such as low-dose cyclophosphamide, together with restoration of cytotoxic T-cell and NK-cell activity; effects on myeloid-derived suppressor cells are agent-dependent.</li>
<li>Suppression of hypoxia-adaptive and treatment-induced stromal responses, including reduced HIF signaling relative to some maximum-tolerated-dose schedules.</li>
<li>Reduction or altered selection of cancer stem-like and tumor-initiating cell populations and attenuation of chemotherapy-induced stromal programs that can promote recurrence and metastasis.</li>
<li>Direct cytostatic or cytotoxic effects on cancer cells determined by the specific chemotherapeutic agent used; these effects generally occur at lower peak exposure than conventional maximum-tolerated-dose treatment.</li>
<li>Reduced opportunity for tumor and vascular recovery between treatment cycles, potentially modifying the development of acquired therapeutic resistance; resistance to metronomic therapy can nevertheless occur.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> There is no single pharmacokinetic profile because metronomic chemotherapy describes a dosing schedule rather than a molecular entity. Oral agents are particularly suited to metronomic administration because frequent dosing can maintain repeated or sustained low systemic exposure. Lower peak concentrations and lower dose per administration distinguish many metronomic schedules from maximum-tolerated-dose chemotherapy, but cumulative exposure can remain substantial. Drug-specific absorption, metabolism, renal or hepatic function, active metabolites, and cumulative toxicities remain clinically important.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Metronomic chemotherapy is primarily schedule-driven rather than defined by a particular in-vitro concentration. Experimental concentrations must therefore be interpreted in relation to the individual drug, exposure duration, and repeated-dose schedule. Short high-concentration in-vitro experiments can poorly model the chronic low-exposure biology of clinical metronomic treatment. Antiangiogenic and immune effects may occur at exposures different from those required for maximal direct tumor-cell killing.</p>

<p><b>Clinical evidence status:</b> RCT / Phase III evidence in selected cancers and schedules, with additional Phase II, maintenance, adjuvant, and metastatic-disease evidence. Randomized Phase III studies have demonstrated clinically meaningful benefit for specific regimens, including prolonged low-dose capecitabine in high-risk nasopharyngeal carcinoma and triple-negative breast cancer. Metronomic chemotherapy is not one universally standardized or separately approved treatment entity; efficacy, toxicity, and clinical adoption remain drug-, cancer-, dose-, and schedule-specific.</p>


<h3>Metronomic Chemotherapy Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tumor angiogenesis and endothelial cells</td>
<td>↓ vascular support</td>
<td>↓ proliferating tumor-associated endothelial cells; relatively less injury to quiescent vasculature</td>
<td>↓ Angiogenesis</td>
<td>Canonical mechanism. Frequent dosing limits endothelial recovery during drug-free intervals and continuously pressures the tumor vasculature.</td>
</tr>
<tr>
<td>2</td>
<td>Thrombospondin-1 antiangiogenic signaling</td>
<td>Indirect ↓ growth</td>
<td>↑ TSP-1 in responsive endothelial and host compartments</td>
<td>↑ Endogenous angiogenesis inhibition</td>
<td>TSP-1 is a mechanistically important mediator of low-dose metronomic effects for several agents, particularly cyclophosphamide models.</td>
</tr>
<tr>
<td>3</td>
<td>VEGF and proangiogenic signaling</td>
<td>↓ VEGF signaling (context-dependent)</td>
<td>↓ endothelial VEGF-dependent proliferation</td>
<td>↓ Neovascularization</td>
<td>VEGF suppression or reduced VEGF pathway activity contributes to the antiangiogenic phenotype, but magnitude varies by agent and tumor model.</td>
</tr>
<tr>
<td>4</td>
<td>Regulatory T cells and antitumor immunity</td>
<td>Indirect ↑ immune-mediated killing</td>
<td>↓ Treg; ↑ effector T-cell and NK-cell activity (agent-dependent)</td>
<td>↓ Tumor immune tolerance</td>
<td>Best established with metronomic cyclophosphamide. Treg depletion is not necessarily sustained indefinitely and should not be generalized to every chemotherapeutic agent.</td>
</tr>
<tr>
<td>5</td>
<td>Myeloid suppressor cells and immune microenvironment</td>
<td>Indirect ↓ survival</td>
<td>↓ MDSC activity (agent-dependent); ↑ antitumor immunity</td>
<td>Immune reprogramming</td>
<td>Particularly relevant to selected agents and combinations such as gemcitabine-containing schedules rather than a universal property of all metronomic chemotherapy.</td>
</tr>
<tr>
<td>6</td>
<td>HIF-1α and tumor hypoxia adaptation</td>
<td>↓ HIF-1α (model-dependent)</td>
<td>↓ maladaptive hypoxic signaling in tumor microenvironment</td>
<td>↓ Hypoxia-driven progression and metastatic adaptation</td>
<td>Low-dose metronomic schedules can avoid or counter HIF induction observed after some maximum-tolerated-dose regimens.</td>
</tr>
<tr>
<td>7</td>
<td>Cancer stem cells and tumor-initiating cells</td>
<td>↓ CSC populations (model-dependent)</td>
<td>↔</td>
<td>↓ Stemness, recurrence potential, and dissemination</td>
<td>Metronomic or chemo-switch schedules have reduced CD133-positive and other stem-like populations in preclinical studies; newer TNBC spheroid work also supports sustained suppression of stemness programs.</td>
</tr>
<tr>
<td>8</td>
<td>Stromal activation and therapy-induced survival signaling</td>
<td>↓ stromal-supported survival</td>
<td>↓ chemotherapy-induced CAF activation (model-dependent)</td>
<td>↓ Tumor repopulation and metastatic support</td>
<td>Metronomic scheduling can reduce the persistent stromal activation and tumor-initiating-cell induction associated with intermittent high-dose chemotherapy.</td>
</tr>
<tr>
<td>9</td>
<td>Direct tumor-cell proliferation and cell death</td>
<td>↓ proliferation; ↑ cell death (agent-dependent)</td>
<td>↓ toxicity relative to MTD schedules in many regimens</td>
<td>Direct cytostatic or cytotoxic activity</td>
<td>The molecular mechanism follows the chemotherapy drug itself. This is therefore not a single conserved pathway of metronomic scheduling.</td>
</tr>
<tr>
<td>10</td>
<td>Therapeutic resistance and tumor repopulation</td>
<td>↓ recovery and repopulation; resistance may still emerge</td>
<td>↔</td>
<td>Reduced treatment-free recovery pressure</td>
<td>Frequent exposure and multicompartment targeting may reduce some resistance-promoting effects of intermittent MTD therapy, but metronomic chemotherapy is not resistance-proof.</td>
</tr>
<tr>
<td>11</td>
<td>Chemosensitization and combination therapy</td>
<td>↑ treatment response (context-dependent)</td>
<td>Variable</td>
<td>↑ Combination efficacy</td>
<td>Can complement antiangiogenic therapy, immunotherapy, radiotherapy, or conventional chemotherapy, but synergy depends strongly on drug, dose, sequence, and tumor type.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Heterogeneous response</td>
<td>↓ peak toxicity but persistent or cumulative toxicity remains possible</td>
<td>Schedule-specific therapeutic window</td>
<td>No universal metronomic dose exists. Optimal dose and schedule vary by drug and tumor. Chronic myelosuppression, gastrointestinal toxicity, hand-foot syndrome, hepatic or renal constraints, and other toxicities remain agent-specific; lower dose does not mean nontoxic.</td>
</tr>
</tbody>
</table>






Pathway results for Effect on Cancer / Diseased Cells

NA, unassigned(tgid=0) ⓘ

NA↑, 1,   NA↝, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp7↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 4,   tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 2,   CSCs↓, 3,   CSCs?, 1,   CSCs↑, 1,   TumCG↓, 3,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

EMT↓, 1,   TSP-1↑, 6,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   Hif1a↓, 3,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

DCells↑, 1,   Imm↑, 6,   T-Cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

chemoR↓, 1,   ChemoSen↑, 1,   Dose↝, 5,   Dose↓, 2,   eff↝, 3,   eff↑, 4,   RadioS↑, 1,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 3,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   ChemoSideEff↓, 3,   OS↑, 8,   PFS↑, 3,   PFS?, 1,   QoL↑, 2,   Remission↑, 1,   toxicity↓, 4,   toxicity↝, 3,   TumVol↓, 3,   Weight↑, 1,  
Total Targets: 48

Pathway results for Effect on Normal Cells

Functional Outcomes(tgid=23) ⓘ

ChemoSideEff↓, 1,   toxicity↓, 3,   toxicity?, 1,  
Total Targets: 3

Research papers

Year Title Authors PMID Link Flag
2024Molecular Iodine Improves the Efficacy and Reduces the Side Effects of Metronomic Cyclophosphamide Treatment against Mammary Cancer ProgressionEvangelina Delgado-GonzálezPMC11354407https://pmc.ncbi.nlm.nih.gov/articles/PMC11354407/0
2026Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular SubtypesHanxing ZhouPMC13240560https://pmc.ncbi.nlm.nih.gov/articles/PMC13240560/0
2026Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao42380630https://pubmed.ncbi.nlm.nih.gov/42380630/0
2026Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive SignalPiotr Jan WysockiPMC13463986https://pmc.ncbi.nlm.nih.gov/articles/PMC13463986/0
2025Metronomic chemotherapy and breast cancer: a critical evaluation of its role in the new landscape of therapeuticsChiara Guarini39422380https://pubmed.ncbi.nlm.nih.gov/39422380/0
2025Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?Elena Battaiotto39627044https://pubmed.ncbi.nlm.nih.gov/39627044/0
2025Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancerYumin SunPMC12808031https://pmc.ncbi.nlm.nih.gov/articles/PMC12808031/0
2025Metronomic Chemotherapy: A Novel Approach in Cancer TreatmentMangal Charan MurmuPMC12906784https://pmc.ncbi.nlm.nih.gov/articles/PMC12906784/0
2024Metronomic chemotherapy and drug repurposing: A paradigm shift in oncologyNusrat JanPMC10837507https://pmc.ncbi.nlm.nih.gov/articles/PMC10837507/0
2024Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal CarcinomaYi-Feng YuPMC11491245https://pmc.ncbi.nlm.nih.gov/articles/PMC11491245/0
2024Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world studyShuhui Dong38936007https://pubmed.ncbi.nlm.nih.gov/38936007/0
2024Metronomic chemotherapy in cancer treatment: new wine in an old bottleHuai-liang WuPMC11209710https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/0
2024Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapyOyku Yagmur BasarPMC11133583https://pmc.ncbi.nlm.nih.gov/articles/PMC11133583/0
2022Metronomic Chemotherapy in Prostate CancerPiotr J WysockiPMC9143236https://pmc.ncbi.nlm.nih.gov/articles/PMC9143236/0
2021Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen34111416https://pubmed.ncbi.nlm.nih.gov/34111416/0
2020Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancersLuana SchitoPMC7507002https://pmc.ncbi.nlm.nih.gov/articles/PMC7507002/0
2018Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three casesGiovanni BrandiPMC6020209https://pmc.ncbi.nlm.nih.gov/articles/PMC6020209/0
2013Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cellsMarta Vives23649709https://pubmed.ncbi.nlm.nih.gov/23649709/0
2013Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular CarcinomaTakuji TorimuraPMC3799193https://pmc.ncbi.nlm.nih.gov/articles/PMC3799193/0
2011Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular CarcinomaHideki IwamotoPMC3050862https://pmc.ncbi.nlm.nih.gov/articles/PMC3050862/0
2010Durable complete response of hepatocellular carcinoma after metronomic capecitabineGiovanni Brandi21388070https://pubmed.ncbi.nlm.nih.gov/21388070/0
2010Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinomaPierluigi Ballardini21302626https://pubmed.ncbi.nlm.nih.gov/21302626/0
2003Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapyGuido BocciPMC240719https://pmc.ncbi.nlm.nih.gov/articles/PMC240719/0